Streetbeat News

Earnings

HLTH

Cue Health projects its Q1 2024 revenue to be between $9M and $11M, significantly lower than the estimated $28.921M.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:27 pm

FTCI

FTC Solar projects a decrease in Q1 2024 revenue compared to Q4 2023, marking it as the year's low point. However, the company anticipates sequential revenue growth thereafter, with a significant portion expected in the latter half of 2024. FTC Solar aims to reach breakeven on an Adjusted EBITDA basis by Q3 and achieve profitability in Q4. The guidance for Q4 2023 was actual revenue of $23.2 million, with Q1 2024 revenue expected to be between $10.0 and $15.0 million.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:27 pm

S

SentinelOne shares dropped following the announcement of their Q4 financial results and future guidance.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:26 pm

CHRS

Coherus BioSciences projects its R&D and SG&A expenses for FY24 to be between $250M and $265M.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:25 pm

HEAR

Turtle Beach (NASDAQ:HEAR) reported Q4 earnings of $0.47 per share, missing the $0.60 estimate, and sales of $99.54M, missing the $111.60M estimate. This represents a 370% increase in earnings per share over the same period last year but a 1.35% decrease in sales.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 8:25 pm

PATH

UiPath, Inc. (NYSE:PATH) reported Q4 earnings of 22 cents per share, surpassing the consensus estimate of 16 cents. Sales reached a record $405.253 million, beating estimates and marking a 31.34% year-over-year increase. This quarter marked UiPath's first as a GAAP profitable company. The company forecasts Q1 revenue between $330 million to $335 million, below the $347.851 million estimate, and FY 2025 revenue between $1.555 billion to $1.56 billion, above the $1.531 billion estimate.

Portfolio Pulse from Erica Kollmann

March 13, 2024 | 8:25 pm

AE

Adams Resources & Energy (AMEX:AE) reported Q4 earnings, beating estimated earnings by 138% with an EPS of $0.03 versus an estimate of $-0.08. However, revenue was down $37.97 million from the same period last year. In the previous quarter, the company missed EPS estimates, resulting in a 3.0% share price drop the next day.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:25 pm

AYRWF

JUSHF

MRMD

MSOS

MariMed Inc. (OTC:MRMD) reported a 48% increase in wholesale revenue for 2023, with projections of over 20% growth for 2024, despite its CY24 sales guidance being below expectations. The company trades at 4.6x EBITDA, below the MSO average of 7.3x. Analyst Pablo Zuanic maintains an Overweight rating on MRMD, citing strong wholesale growth and underutilized brand power, despite a 21% decrease in MRMD shares over the past 90 days. The MSOS ETF (NYSE:MSOS) has only 1% ownership in MariMed, compared to 10-14% for companies like Jushi (OTC: JUSHF) and AYR (OTC:AYRWF), contributing to MariMed's underperformance. Zuanic sees limited downside risk and potential for future gains, especially with strategic expansions.

Portfolio Pulse from Nicolás Jose Rodriguez

March 13, 2024 | 8:25 pm

LMB

Limbach Holdings (NASDAQ:LMB) reported Q4 earnings with an EPS of $0.44, beating estimates by 10.0% but with a revenue decrease of $792 thousand from the previous year. The company had previously beaten EPS estimates in Q3 2023, leading to an 18.0% share price increase the next day.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:25 pm

PATH

UiPath (NYSE:PATH) reported Q4 earnings with a 38.0% beat on estimated EPS, reporting $0.22 versus an estimate of $0.16. Revenue increased by $96.70 million from the same period last year. The company has a history of beating EPS estimates, leading to a share price increase of 27.0% the day after last quarter's earnings were announced.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 8:25 pm